Drug reference

pipenzolate methyl bromide

Semisynthetic anticholinergic, Quaternary compound · Antispasmodic

Semisynthetic anticholinergic, Quaternary compoundAntispasmodic

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

—

none in our sources

PREGNANCY

—

not curated

Mechanism

Pipenzolate methyl bromide is a semisynthetic anticholinergic compound promoted for its antispasmodic effects in conditions like flatulent dyspepsia, infantile colics, and abdominal cramps.

Indications

Flatulent dyspepsiaInfantile colicsAbdominal cramps

Dosing

Adult: 5–10 mg oral
Pediatric: 2–3 mg oral

Related guidelines

Intra-abdominal infection

WSES · Surgery · 2017

Irritable bowel syndrome

ISG · Gastroenterology · 2023

Extrapulmonary tuberculosis

ICMR · Infectious Diseases · 2022

Other Semisynthetic anticholinergic, Quaternary compound drugs

atropine methonitrate

Ask House about pipenzolate methyl bromide

Continue into a citation-backed clinical answer with the drug context already attached.

Open in workspace Ask House about this drug

Sources: KD Tripathi 7e·Verified: 2026-05-10 · House clinical team